Pregabalin Tablet, Film Coated, Extended Release
Product Images NDC 72888-049

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 72888-049). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advagen Pharma Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin Extended-release Tablets, 165 mg (NDC 72888-050-30)

Pregabalin Extended-release Tablets, 165 mg (NDC 72888-050-30)
This is a medication called Pregabalin in an extended-release tablet form with a strength of 165mg. It is packaged in a child-resistant container, and a medication guide is provided separately to each patient. The medication must be stored at a temperature of 20°C to 25°C, and excursions permitted between 15°C and 30°C. This medication should only be taken as per the prescribing information. The product is distributed by Advagen Pharma Limited of Plainsboro, NJ, and manufactured by Rubicon Research Private Limited of Ambernath, India.*
FDA Label Image

Pregabalin Extended-release Tablets, 330 mg (NDC 72888-051-30)

Pregabalin Extended-release Tablets, 330 mg (NDC 72888-051-30)
This is a medication containing 330mg of Pregabalin, USP in extended-release tablet form. The dosage and use information is provided in the accompanying prescribing information. It should be stored in a tight, child-resistant container at a temperature between 20°C to 25°C (68°F to 77°F), with permitted excursions between 15°C and 30°C (between 59°F and 86°F). The medication guide should be provided separately to each patient. This medication should be kept out of reach of children. It is distributed by Advagen Pharma Limited, located in Plainsboro, NJ, and manufactured by Rubicon Research Private Limited in India. However, no indication of the purpose of this medication is provided.*
FDA Label Image

Pregabalin Extended-release Tablets, 82.5 mg (NDC 72888-049-30)

Pregabalin Extended-release Tablets, 82.5 mg (NDC 72888-049-30)
This is a description of a medication containing Pregabalin, USP with a dosage of 82.5mg. Each tablet contains FD&C Yellow No.5 (tartrazine) as a color additive. The prescribing information, storage instructions, and guidelines for dispensation are also provided. This medication is distributed by Advagen Pharma Limited and manufactured by Rubicon Research Private Limited in India. A Medication Guide is provided separately to each patient. Further information, such as medical indications, is not available.*
FDA Label Image

Pregabalin Extended-release Tablets Equation (Pregabalin Er Tab Equation)

Pregabalin Extended-release Tablets Equation (Pregabalin Er Tab Equation)
This text appears to be a formula or equation related to calculating weight in kilograms using the serum creatinine levels in milligrams per deciliter (mg/dL). It also mentions a factor of 0.35 for female patients, but the context and purpose of this equation is not clear.*
FDA Label Image

Pregabalin Extended-release Tablets Figure 1 (Pregabalin Er Tab Figure1)

FDA Label Image

Pregabalin Extended-release Tablets Structure (Pregabalin Er Tab Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.